Stroke

30 days post-treatment, the mean Fugl-Meyer score change was a significant 8.36 points and 7.86 points for the in-clinic and telerehabilitation groups, respectively.

An episode of slurred speech, dizziness, and severe headache resolved after 10 minutes. What do you suspect?

An assessment of 230 poststroke patients determined that neurorehabilitation outcomes and length of stay did not differ between those with poststroke epileptic seizures and those without.

The head of the Cleveland Clinic stroke program and medical director of the Comprehensive Stroke Center sat down with Neurology Live for an in-depth discussion on stroke certifications, advanced treatment technology, and the ever-evolving concept of "time is brain."

Neurology News Network for the week ending June 8, 2019.

Are his symptoms related to a fall that occurred 2 years earlier at work?

The soft, garment-like device assists with forward propulsion and ground clearance in patients with gait impairments accumulated after experiencing a stroke.

The program director of neurology at Zucker School of Medicine, Northwell Health, reviewed the contributions of neurologist S. Weir Mitchell, MD, and how today’s neurologists can gain insights for their own practice from Mitchell’s complicated history.

The assistant clinical investigator, Neuro Vascular Brain Imaging Unit, NINDS, further elaborated on the findings of a retrospective analysis that reported that approximately half of stroke patients who present outside of thrombolysis treatment time windows without large vessel occlusion may benefit from reperfusion therapy.

Despite a 40-fold increase in the use of LAAC in a 9-year period, those who had a history of stroke with major bleeds and higher comorbidity were less likely to have LAAC.

Similar rates of successful clinical and procedural EVT outcomes were reported in patients with and without prestroke disability; however, prospective studies are needed to confirm this finding.

The research fellow in the Department of Radiology at Mayo Clinic Jacksonville spoke about the reasoning for conducting this study and what the findings mean for physicians in clinical practice.

A patient with worsening atrial fibrillation experiences improvement of his symptoms and heart rate with chiropractic manipulation. More in this podcast.

This is the second aneurysm adjunctive stent to be granted premarket approval for treatment of wide-neck, intracranial aneurysms in conjunction with embolic detachable coils.

The recommendations translate important scientific knowledge and innovations in clinical care into improvements in patient outcomes.

The director of the Pediatric Stroke Program at CHOP discussed the findings of a single-center study exploring the incidence of children presenting with acute arterial ischemic stroke who may have been eligible for mechanical thrombectomy.

These new studies describe events and risks that go after, or before, the onset of symptoms.

Insights about where stem cell treatment of neurological diseases is headed.

The director of the Pediatric Stroke Program at CHOP spoke about the need to improve early recognition and assessments in pediatric stroke, and how ultimately, awareness of the condition is a huge step toward achieving this goal.

Recent findings challenge previous assumptions about the genesis of atherosclerosis.

When combined with high-intensity statin therapy, treatment with alirocumab resulted in a 27% reduction in stroke risk, and 15% reduction in all-cause mortality.

Experts worry that the new criteria for certification of thrombectomy-capable stroke centers are insufficient to ensure quality of care.

The chair of Applied Neuroimaging and head of Neuroimaging Sciences and Edinburgh Imaging at the University of Edinburgh spoke about what the physician community needs to know about utilizing isosorbide mononitrate and cilostazol for lacunar stroke.

An escalating, combination dose of isosorbide mononitrate and cilostazol was shown to be well tolerated, with 72% of patients achieving full or ≥50% partial doses, the primary outcome, by the end of the 8-week treatment period.

The FDA issued a reminder that improper use of the Stryker Wingspan Stent System can result in an increased risk for stroke or mortality. The agency advises against using the system when the onset of symptoms is within 7 days or less of treatment or for the treatment of transient ischemic attacks.